| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.6 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | 0.18 | 0.6 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.6 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.6 |